IceCure’s ProSense shows pain reduction efficacy in endometriosis study

IceCure announced encouraging findings from a recently published, independently conducted study evaluating the efficacy and safety of personalized percutaneous single-probe liquid-nitrogen cryoablation with ProSense in treating symptomatic abdominal wall endometriosis, or AWE. AWE is a debilitating condition, often occurring in surgical scars after caesarean sections, characterized by cyclic pain and a palpable mass. The peer-reviewed study, published in Journal of Personalized Medicine, was conducted in Nimes, France. The study enrolled 14 patients. Key study highlights include the following: substantial pain relief: median pain scores declined from 8/10 pre-treatment to 0/10 at 3-month follow-up; high procedural efficacy: MRI confirmed complete coverage of the ablation zone and disappearance of hemorrhagic inclusions in all cases; median ablation and overall procedural times were 15 minutes and 93 minutes, respectively. No peri- or post-procedural complications were reported; no visible scars were observed. Only two patients – 14% – required a second treatment using the same modality, both achieving satisfactory outcomes. According to the WHO, endometriosis affects about 10% of women who are at reproductive age globally.